Assessments of serum NGAL concentration made it possible to distinguish patients with IBD from healthy subjects with 76.1% sensitivity and 60.9% specificity (at a 129 ng/mL cut-off level of NGAL). This evidence concerns the gene LCN2 and inflammatory bowel disease.